Celprogen’s Novel CEP1430 & CEP1507 Compounds for Targeting Advanced Stage Pancreatic Cancer Patients

On April 13, 2016 Celprogen reported they successfully completed their pre-clinical evaluation of CEP1430 and CEP1507 compounds as selectively targeting Pancreatic Cancer stem Cell population that contribute to treatment related resistance (Press release, Celprogen, APR 13, 2016, View Source [SID:1234510892]). Both compounds demonstrated growth inhibition of pancreatic tumors in patient derived xenograft (PDX) cancer models by 80% to 85%. The results of the study will be presented in an abstract format on Monday, April 18, 2016 at American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting in New Orleans. These compounds are Celprogen’s propriety compounds for targeting Pancreatic Cancer Stem Cells (CSC) and Circulating Tumor Cells (CTC) in patients with advanced stages of pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The present invention relates to Drug Discovery programs at Celprogen that identify potential drug candidates for the treatment of pancreatic cancer. At present Celprogen is exploring partnership with Pharmaceutical Industry to move promising drug candidates forward to the clinical development and increasing the armament of drugs against pancreatic cancer. CEP1430 is a selective inhibitor of CSC that can be administrated orally and does not exhibit sign of toxicity. The mechanism of cell death also indicates that these molecules will greatly enhance the efficacy of immune based approaches to improve outcome in pancreatic cancer patients. These pancreatic Stem Cell selective inhibitors are expected to eradicate tumors, improve quality of life and prolong and/or overall survival and patients bearing pancreatic tumors.

OncoSec to Host Webcast and Panel Discussion on New Melanoma Clinical Data

On April 13, 2016 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, reported that it will host a webcast to provide an overview and panel discussion regarding new clinical data that will be featured as an oral presentation at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, OncoSec Medical, APR 13, 2016, View Source [SID:1234510751]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be held on Wednesday, April 20, 2016 at 11:00 AM ET/8:00 AM PT.

The webcast will include a round table discussion to enable key opinion leaders in the fields of melanoma and immuno-oncology to contribute their respective insights on data from the AACR (Free AACR Whitepaper) abstract entitled: "Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma" (Abstract #CT134). Webcast participants will include:

Alain Algazi, MD, Skin Cancer Specialist, Melanoma Center, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), UCSF; Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center
Robert Andtbacka, MD, CM, Associate Professor, Division of Surgical Oncology, Department of Surgery, University of Utah School of Medicine; Surgeon and Investigator, Intermountain Healthcare and Huntsman Cancer Institute
Sharron Gargosky, PhD, Head of Clinical Development and Operations, OncoSec*
Moderator: Robert Pierce, MD, Chief Scientific Officer, OncoSec
To join via webcast, please use the following link: View Source To listen to the conference call, please dial (877) 731-1960 and enter conference ID number: 84899794. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec’s website: ir.oncosec.com/events.

Tokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016

On April 13, 2016 Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, reported that two presentations on galeterone will be made during poster sessions held at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2016 in New Orleans (Press release, Tokai Pharmaceuticals, APR 13, 2016, View Source;p=RssLanding&cat=news&id=2156705 [SID:1234510747]). Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistance prostate cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Galeterone-induced degradation of the androgen receptor involves inhibition of deubiquitinating enzymes
Date/time: Monday, April 18, 2016, 8 a.m. – 12 p.m. CDT
Location: Section 16
Abstract: 1234
Title: The effect of novel CYP17 inhibitor galeterone on gonadal and tumor progestogen and androgen levels in SCID mice bearing LNCaP prostate cancer xenografts
Date/time: Tuesday, April 19, 2016, 1 – 5 p.m. CDT
Location: Section 1
Abstract: 3490
Additional information, including the presentation schedule and full abstracts, may be found at www.aacr.org. A copy of each presentation will be available on the "Publications & Presentations" page of Tokai’s website, www.tokaipharma.com.

About Galeterone
Galeterone is an oral small molecule that utilizes the established pathways, including CYP17 enzyme and androgen receptor inhibition, of the current second-generation hormonal therapies abiraterone and enzalutamide. Galeterone also introduces a distinct third mechanism – androgen receptor degradation – that decreases the sensitivity of androgen receptors to androgen activity, thus leading to reductions in tumor growth. Tokai is developing galeterone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). ARMOR3-SV, the company’s pivotal Phase 3 study of galeterone in treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant, is evaluating whether administration of galeterone results in a statistically significant increase in radiographic progression-free survival as compared to enzalutamide. Tokai is also evaluating galeterone in mCRPC patients who have shown resistance following treatment with second-generation hormonal agents. Tokai has worldwide development and commercialization rights to galeterone.

TG Therapeutics, Inc. Announces Issuance of Composition of Matter Patent for TG-1101 in the United States

On April 13, 2016 (TG Therapeutics, Inc. (Nasdaq:TGTX) reported that the United States Patent and Trademark Office (USPTO) has issued a patent for the composition of matter of TG-1101, the Company’s novel, glycoengineered monoclonal antibody (Press release, TG Therapeutics, APR 13, 2016, View Source [SID:1234510746]). The patent, U.S. Patent No. 9,234,045 specifically covers the composition of TG-1101, and its use for treating various forms of CD20 expressing leukemia and lymphoma, including chronic lymphocytic leukemia (CLL) and various types of non-Hodgkin’s lymphoma, including follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent was issued to LFB SA and is exclusively licensed to TG Therapeutics pursuant to the Company’s existing license agreement with LFB SA. The issuance affords patent protection for TG-1101 in the US through July of 2029, exclusive of additional patent term extensions also available. TG-1101 is currently being studied in two Phase 3 clinical trials in patients with CLL, with additional registration directed trials in NHL expected to commence in 2016.

"We are excited to announce the issuance of the first U.S. patent for TG-1101 which affords protection through 2029. With composition of matter patents now in place for both TG-1101 and TGR-1202, and an additional later-filed patent application on the combination of TG-1101 and TGR-1202, we believe we have established a very strong intellectual property position for the two components of our proprietary ‘TG-1303′ regimen that provides a very attractive exclusivity period without the risk of generic competition for many years to come," stated Michael S. Weiss, the Company’s Executive Chairman and Interim CEO. Mr. Weiss continued, "We remain focused on continuing to strengthen our intellectual property position through the issuance of additional patents for both TG-1101 and TGR-1202 individually as well as in combination here in the US and abroad."

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform

On April 13, 2016 Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Sarcoma Foundation of America, reported that Advaxis has been awarded the 2016 Vision of Hope Award for their efforts to advance an immunotherapy platform to fight osteosarcoma in patients (Press release, Advaxis, APR 13, 2016, View Source [SID:1234510743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The Sarcoma Foundation of America is proud to present the Vision of Hope Award to Advaxis Immunotherapies, a trailblazer in the osteosarcoma space," said Bert Thomas IV, Ph.D., Chief Executive Officer of the Sarcoma Foundation of America. "Their innovative technology gives hope to sarcoma patients in critical need of new treatments and paves the way for additional immunotherapies to offer patients a brighter future."

Advaxis is the first biotechnology company to ever receive the award for their work in the development of ADXS-HER2, an Lm Technology that has received an orphan drug designation from the FDA and EMA for treatment of osteosarcoma. In a study examining canine osteosarcoma, 18 dogs received either 2×108, 5×108, 1×109 or 3.3×109 CFU of ADXS–HER2 post-completion of surgery and adjuvant chemotherapy with 15 dogs showing an induced antigen-specific response within 6 months of immunotherapy administration. Additionally, treatment with ADXS-HER2 reduced the incidence of metastatic disease and prolonged survival relative to a historical control group with only low-grade, transient side-effects.

Osteosarcoma is the most common primary bone tumor in dogs, with more than 10,000 dogs annually diagnosed, and the most common bone cancer in children and teens. It is the third most common cancer in teens after lymphomas and brain tumors. HER2 is expressed in approximately 40 to 60 percent of pediatric and canine osteosarcomas and in pulmonary metastatic disease, providing a strong rationale for HER2 targeted immunotherapy in these cancers.

"We are honored to be chosen as a recipient of this prestigious Award from the Sarcoma Foundation of America," said Daniel J. O’Connor, President and Chief Executive Officer of Advaxis. "We recognize the serious unmet need to treat children and young adults battling this life-threatening disease and are proud to work towards developing immunotherapies that may help change the course of osteosarcoma patients’ lives."

Advaxis will receive the Vision of Hope Award at the Sarcoma Foundation of America 14th Annual Fundraising Event, "A Celebration of Life," on Thursday, May 12, 2016 at 6:00 PM EDT in New York City. For further information and to register, visit the Sarcoma Foundation of America’s website.

About Sarcoma

Sarcoma is a rare cancer in adults, accounting for 1 percent of all adult cancers, but rather prevalent in children, accounting for about 15 percent of all childhood cancers. At any one time, 50,000 patients and their families are struggling with sarcoma. Every year, nearly 15,000 new cases are diagnosed and about 6,000 people die from the disease.

About the Sarcoma Foundation of America

The Sarcoma Foundation of America (SFA), a 501(c)(3) nonprofit charitable organization, is an advocate for increased research to find new and better therapies with which to treat patients with sarcoma. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy efforts on behalf of sarcoma patients. For more information, please visit www.curesarcoma.org.

About ADXS-HER2

ADXS-HER2 is an Lm Technology immunotherapy product candidate being developed by Advaxis to target HER2 expressing cancers. ADXS-HER2 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of osteosarcoma. Advaxis is developing ADXS-HER2 for both human and animal health, and has seen encouraging data in canine osteosarcoma, which is considered a model for human osteosarcoma. Advaxis has licensed ADXS-HER2 to Aratana Therapeutics, Inc. for animal health therapeutics. Aratana expects to receive a conditional USDA license by the end of 2016 to market and sell ADXS-HER2 for dogs with canine osteosarcoma.